Related references
Note: Only part of the references are listed.Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes
Noa G. Holtzman et al.
NEURO-ONCOLOGY (2021)
Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy
Jing Pan et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)
Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy
Jochen Buechner et al.
BLOOD ADVANCES (2021)
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature
Ajay Major et al.
LEUKEMIA & LYMPHOMA (2021)
Neurotoxicity Biology and Management
Husain Danish et al.
CANCER JOURNAL (2021)
Disparities in the use of checkpoint inhibitors and CAR T-cell therapy: A systematic review.
Devika R. Jutagir et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
John E. Levine et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions
Eline van Overbeeke et al.
DRUG DISCOVERY TODAY (2021)
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
Ana Cordeiro et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies
Ying Wang et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Ibrahim Yakoub-Agha et al.
HAEMATOLOGICA (2020)
Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)
George R. Nahas et al.
LEUKEMIA & LYMPHOMA (2020)
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Nirali N. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)
Robert David Sandler et al.
FRONTIERS IN IMMUNOLOGY (2020)
Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome
Nirav N. Shah et al.
BLOOD ADVANCES (2020)
Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma
Paolo Strati et al.
BLOOD ADVANCES (2020)
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma
Kitsada Wudhikarn et al.
BLOOD CANCER JOURNAL (2020)
American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States
Zahra Mahmoudjafari et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Kris M. Mahadeo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Cytopenias after Chimeric Antigen Receptor T-Cells (CAR-T) Infusion; Patterns and Outcomes
Andrew Shaefer et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults
Paul La Rosee et al.
BLOOD (2019)
Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy
Hamza Hashmi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
CAR-T the living drugs, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
Delong Liu
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
Rebecca A. Gardner et al.
BLOOD (2019)
Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma
Max Topp et al.
BLOOD (2019)
Toxicities of CD19 CAR-T cell immunotherapy
Alexandre V. Hirayama et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
CAR T Cell Toxicity: Current Management and Future Directions
Lucrecia Yanez et al.
HEMASPHERE (2019)
In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy
Jorge Garcia Borrega et al.
HEMASPHERE (2019)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
Robert Q. Le et al.
ONCOLOGIST (2018)
Clinical Utilization of Chimeric Antigen Receptors T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation
Ankit J. Kansagra et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy
Noelle Frey et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline
Timothy Gilligan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
Betty R. Ferrell et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
Laura C. Cappelli et al.
ARTHRITIS CARE & RESEARCH (2017)
Cancer Immunotherapy An evidence-based overview and implications for practice
Virginia Bayer et al.
CLINICAL JOURNAL OF ONCOLOGY NURSING (2017)
Delirium screening anchored in child development: The Cornell Assessment for Pediatric Delirium
Gabrielle Silver et al.
PALLIATIVE & SUPPORTIVE CARE (2015)
Understanding Immune Checkpoint Inhibitors for Effective Patient Care
Krista M. Rubin
CLINICAL JOURNAL OF ONCOLOGY NURSING (2015)
Cornell Assessment of Pediatric Delirium: A Valid, Rapid, Observational Tool for Screening Delirium in the PICU
Chani Traube et al.
CRITICAL CARE MEDICINE (2014)
Etoposide Selectively Ablates Activated T Cells To Control the Immunoregulatory Disorder Hemophagocytic Lymphohistiocytosis
Theodore S. Johnson et al.
JOURNAL OF IMMUNOLOGY (2014)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N. Kochenderfer et al.
BLOOD (2012)
Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementability
Richard N. Shiffman et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2012)
Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation - On behalf of the Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH)
FB Taylor et al.
THROMBOSIS AND HAEMOSTASIS (2001)
Share Paper
